Effects of pegylated interferon plus ribavirin on naive and retreat chronic hepatitis C patients: a retrospective study
10.3760/cma.j.issn.1671-7368.2012.11.013
- VernacularTitle:聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎初治与再治患者的回顾性研究
- Author:
Zongguo YANG
;
Peiyan YE
;
Xiaorong CHEN
;
Cheng LIU
- Publication Type:Journal Article
- Keywords:
Hepatitis C,chronic;
Interferon alfa-2a;
Ribavirin
- From:
Chinese Journal of General Practitioners
2012;(11):836-839
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of pegylated interferon plus ribavirin on naive and retreated chronic hepatitis C (CHC) patients.Methods A total of 67 CHC patients were divided into naive group (n =35) and retreat group (n =32) based on their treatment history.And their virological responses [rapid virological response (RVR),early virological response (EVR),virological response to etravirine (ETR) and sustained virological response (SVR)] and risk factors were analyzed.Results ①RVR and EVR of naive group were 60％ (n =21) and 77％ (n =27),respectively,and the retreat group were 28％ (n =9),53％ (n =17).The differences between the two groups were significant (both P ＜ 0.05).On the contrary,CHC patients in both groups might achieve similar ETR and SVR rates (P ＞ 0.05) ; ② The relapse rate in the retreat group was higher than that in the naive group (22％ vs.10％).But the differences had no statistical significance (P ＞ 0.05) ; ③ CHC patients in the retreat group could achieve similar responses,including RVR,EVR,ETR and SVR (P ＞ 0.05) whether treated previously with standard interferon or pegylated interferon; ④ According to muhivariable logistic regression analysis,the retreated genotype 1 CHC patients has a lower SVR rate compared with naive genotype non-1 counterparts (OR =0.29 and 0.26,all P ＜ 0.05).Conclusions CHC patients in the naive group could achieve higher virological responses and a lower relapse rate compared to those in the retreat group.The previous treatment regimeu has no significant effect on virological responses of CHC patients retreated with Peg-IFN plus ribavirin.Genotype 1 and retreatment are both risk factors of achieving SVR.
